Zhitong Finance App News, China Biopharmaceutical (01177.HK) announced that the national Class 1 innovative drug TQB3909 tablets (BCL-2 inhibitors) independently developed by the Group's subsidiary, Zhengda Tianqing Pharmaceutical Group Co., Ltd. (Zhengda Tianqing), have submitted a new drug marketing application to the China National Drug Administration Drug Evaluation Center (CDE) and accepted for the treatment of adult chronic lymphocytic leukemia/microlymphocytic lymphoma (CLL/SLL).
智通財經·08/04/2026 08:57:03
語音播報
Zhitong Finance App News, China Biopharmaceutical (01177.HK) announced that the national Class 1 innovative drug TQB3909 tablets (BCL-2 inhibitors) independently developed by the Group's subsidiary, Zhengda Tianqing Pharmaceutical Group Co., Ltd. (Zhengda Tianqing), have submitted a new drug marketing application to the China National Drug Administration Drug Evaluation Center (CDE) and accepted for the treatment of adult chronic lymphocytic leukemia/microlymphocytic lymphoma (CLL/SLL).